This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://linked.opendata.cz/resource/mesh/concept/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n4http://linked.opendata.cz/resource/fda-spl/ingredient/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
n7http://linked.opendata.cz/resource/ndfrt/ingredient/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C1851
rdf:type
owl:Class
rdfs:label
Bortezomib
owl:equivalentClass
_:vb630398
nci:A7
nci:C17778
nci:A8
nci:C63923
nci:P106
Organic Chemical Pharmacologic Substance
nci:P108
Bortezomib
nci:P175
681239
nci:P207
C1176309
nci:P210
179324-69-7
nci:P302
Multiple Myeloma; Advanced Thyroid Cancer
nci:P303
Multiple myeloma; myelogenous leukemia; ovarian epithelial; fallopian tube; or primary peritoneal cancer; prostate cancer; transitional cell cancer of the bladder; renal cancer; or ureter; unspecified solid tumors; Waldenstrom's Macroglobulinemia Colorectal cancer; breast cancer; cervical cancer; vaginal cancer; non-Hodgkin's lymphoma; Hodgkin's lymphoma; melanoma Bile duct or gallbladder adenocarcinoma; gastric cancer; gastrointestinal junction carcinoma; glioma; head and neck cancer; hepatocellular carcinoma; lung cancer; small cell and non-small cell; lymphoproliferative disorders; thyroid cancer
nci:P319
69G8BD63PP
nci:P322
FDA
nci:P325
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A drug used to treat multiple myeloma. It is also used to treat mantle cell lymphoma in patients who have already received at least one other type of treatment and is being studied in the treatment of other types of cancer. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>
nci:P329
43560
nci:P330
43560
nci:P350
C19H25BN4O4
nci:P366
Bortezomib
nci:P368
CHEBI:52717
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>PS-341</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>BORTEZOMIB</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>69G8BD63PP</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>LDP 341</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Velcade</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>bortezomib</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000269133</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Bortezomib</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>MLN341</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>velcade</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000413734</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>PS341</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>PS-341</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000046719</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>DCP</n0:term-source><n0:source-code>31947</n0:source-code></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C1851
owl:sameAs
n4:69G8BD63PP n7:N0000010079
n5:hasConcept
n6:M0350110
Subject Item
_:vb630398
rdf:type
owl:Class
owl:intersectionOf
_:vb731431
Subject Item
_:vb651447
rdf:type
owl:Restriction
owl:onProperty
nci:R146
owl:someValuesFrom
nci:C17778
Subject Item
_:vb651448
rdf:type
owl:Restriction
owl:onProperty
nci:R124
owl:someValuesFrom
nci:C41597
Subject Item
_:vb651449
rdf:type
owl:Restriction
owl:onProperty
nci:R125
owl:someValuesFrom
nci:C26044
Subject Item
_:vb651450
rdf:type
owl:Restriction
owl:onProperty
nci:R125
owl:someValuesFrom
nci:C20150
Subject Item
_:vb651451
rdf:type
owl:Restriction
owl:onProperty
nci:R125
owl:someValuesFrom
nci:C40821
Subject Item
_:vb731431
rdf:first
nci:C2160
rdf:rest
_:vb751107
Subject Item
_:vb751107
rdf:first
_:vb651447
rdf:rest
_:vb751108
Subject Item
_:vb751108
rdf:first
_:vb651448
rdf:rest
_:vb751109
Subject Item
_:vb751109
rdf:first
_:vb651449
rdf:rest
_:vb751110
Subject Item
_:vb751110
rdf:first
_:vb651450
rdf:rest
_:vb751111
Subject Item
_:vb751111
rdf:first
_:vb651451
rdf:rest
rdf:nil